<p><strong>Background:</strong> Psoriasis is an auto-inflammatory disease condition, with the clinical symptoms of scaling, inflammation and itching. This condition is triggered by external and internal factors such as environment, seasons and free radicles etc. Psorolin B is a proprietary Siddha Medicine indicated for the reduction in the psoriatic symptoms and also for inhibiting the various triggers of psoriasis</p><p><strong>Methods:</strong> In the present paper, the formulation is evaluated for its anti-oxidant effect, anti-glycation effect, enzymatic activity reduction i.e., elastase, collagenase, lipoxygenase and reduction in COX1 and COX 2 by following the standard methods.</p><p><strong>Results:</strong> In the present paper, the formulation is evaluated for its anti-oxidant effect, anti-glycation effect, enzymatic activity reduction i.e., elastase, collagenase, lipoxygenase and reduction in COX1 and COX 2 by following the standard methods. The study results show that the product is able to reduce- free radicle scavenging activity, advanced glycation end products, elastase, collagenase, lipoxygenase and COX1 and COX 2</p><p><strong>Conclusions:</strong> The study results prove that this product can control the pro-inflammatory mediators by inhibiting the triggering factors like free radicles and advanced glycation end products. This also play a major role in inhibiting the elastase and collagenase that helps in reducing the cell cycle turn over. Complete details of the study are explained the paper.<strong></strong></p>
254 EFFECTS OF PPAR-γ AGONIST ON ADVANCED GLYCATION END PRODUCTS-STIMULATED COX-2, PGE2 AND NO PRODUCTIONS IN HUMAN OSTEOARTHRITIC CHONDROCYTES
